Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.
Author
Gesztes, WilliamSchafer, Cara
Young, Denise
Fox, Jesse
Jiang, Jiji
Chen, Yongmei
Kuo, Huai-Ching
Mwamukonda, Kuwong B
Dobi, Albert
Burke, Allen P
Moul, Judd W
McLeod, David G
Rosner, Inger L
Petrovics, Gyorgy
Tan, Shyh-Han
Cullen, Jennifer
Srivastava, Shiv
Sesterhenn, Isabell A
Date
2022-03-30Journal
Scientific ReportsPublisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
TP53 is one of the most frequently altered genes in prostate cancer. The precise assessment of its focal alterations in primary tumors by immunohistochemistry (IHC) has significantly enhanced its prognosis. p53 protein expression and lymphovascular invasion (LVI) were evaluated for predicting metastatic progression by IHC staining of representative whole-mounted prostate sections from a cohort of 189 radical prostatectomy patients with up to 20 years of clinical follow-up. Kaplan-Meier survival curves were used to examine time to distant metastasis (DM) as a function of p53 expression and LVI status. TP53 targeted sequencing was performed in ten tumors with the highest expression of p53 staining. Nearly half (49.8%) of prostate tumors examined showed focal p53 expression while 26.6% showed evidence of LVI. p53(+) tumors had higher pathologic T stage, Grade Group, Nuclear Grade, and more frequent LVI. p53 expression of > 5% and LVI, individually and jointly, are associated with poorer DM-free survival. TP53 mutations were detected in seven of ten tumors sequenced. Four tumors with the highest p53 expression harbored likely pathogenic or pathogenic mutations. High levels of p53 expression suggest the likelihood of pathogenic TP53 alterations and, together with LVI status, could enhance early prognostication of prostate cancer progression.Rights/Terms
© 2022. The Author(s).Identifier to cite or link to this item
http://hdl.handle.net/10713/18450ae974a485f413a2113503eed53cd6c53
10.1038/s41598-022-08826-5
Scopus Count
Collections
Related articles
- p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
- Authors: Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S
- Issue date: 2003
- Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.
- Authors: Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto GJ, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL
- Issue date: 2017 Aug 15
- Clinical significance of p53 alterations in surgically treated prostate cancers.
- Authors: Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A
- Issue date: 2008 Nov
- Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
- Authors: Moul JW
- Issue date: 1999
- Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
- Authors: Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Hussein Al Awamlh B, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, Shariat SF
- Issue date: 2016 May